DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Raised to $13.00

DENTSPLY SIRONA (NASDAQ:XRAY) had its target price hoisted by Wells Fargo & Company from $12.00 to $13.00 in a report released on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target suggests a potential downside of 9.88% from the stock’s current price.

A number of other research analysts also recently weighed in on the stock. Zacks Research downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a research report on Monday, November 10th. Robert W. Baird increased their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday. Barclays initiated coverage on DENTSPLY SIRONA in a report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price objective for the company. JPMorgan Chase & Co. decreased their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Finally, Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $14.69.

DENTSPLY SIRONA Stock Up 13.5%

Shares of DENTSPLY SIRONA stock traded up $1.72 during trading on Friday, reaching $14.43. The stock had a trading volume of 6,790,192 shares, compared to its average volume of 4,743,038. The company has a current ratio of 1.47, a quick ratio of 0.99 and a debt-to-equity ratio of 1.36. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of -3.26, a P/E/G ratio of 1.01 and a beta of 1.01. The stock has a fifty day moving average price of $12.35 and a two-hundred day moving average price of $12.47. DENTSPLY SIRONA has a 52 week low of $9.85 and a 52 week high of $17.34.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 24.34% and a positive return on equity of 17.10%. The firm had revenue of $961.00 million during the quarter, compared to analyst estimates of $926.40 million. During the same period in the prior year, the business posted $0.26 EPS. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts predict that DENTSPLY SIRONA will post 1.84 EPS for the current fiscal year.

Insider Activity at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier sold 82,200 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.50% of the company’s stock.

Institutional Trading of DENTSPLY SIRONA

Hedge funds have recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. grew its holdings in DENTSPLY SIRONA by 2.9% in the 4th quarter. Daiwa Securities Group Inc. now owns 26,814 shares of the medical instruments supplier’s stock valued at $306,000 after buying an additional 767 shares in the last quarter. Arizona State Retirement System boosted its position in shares of DENTSPLY SIRONA by 1.4% in the third quarter. Arizona State Retirement System now owns 58,952 shares of the medical instruments supplier’s stock valued at $748,000 after acquiring an additional 807 shares during the period. True Wealth Design LLC grew its stake in shares of DENTSPLY SIRONA by 49.7% in the third quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock valued at $45,000 after acquiring an additional 1,181 shares in the last quarter. Sivia Capital Partners LLC raised its stake in DENTSPLY SIRONA by 5.3% in the 3rd quarter. Sivia Capital Partners LLC now owns 25,774 shares of the medical instruments supplier’s stock worth $327,000 after purchasing an additional 1,293 shares in the last quarter. Finally, Empowered Funds LLC raised its stake in DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock worth $244,000 after purchasing an additional 1,320 shares in the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Revenue beat and operational actions — Q4 revenue of $961M topped estimates and management announced a $120M annual restructuring to redirect spending into innovation, clinical & sales education, and connected-dentistry initiatives; investors view this as a credible turnaround lever. GlobeNewsWire release
• Positive Sentiment: Capital-allocation shift — Company eliminated its dividend to prioritize debt reduction and share repurchases, signaling management focus on balance-sheet repair and EPS accretion rather than cash returns. GlobeNewsWire release
• Neutral Sentiment: Analyst adjustment — Robert W. Baird raised its price target to $14 and kept a “neutral” rating, signaling tempered upside in analyst expectations despite the restructuring. TickerReport
• Negative Sentiment: EPS miss and impairment-driven loss — Reported GAAP loss (net loss $146M, -$0.74) driven by $144M goodwill/intangible impairments; adjusted EPS $0.27 missed consensus by $0.01. These hits and one-time charges weigh on near-term profitability metrics. GlobeNewsWire release
• Negative Sentiment: Softer FY26 guidance — Management set FY26 adjusted EPS $1.40–$1.50 and revenue $3.5–3.6B, both slightly below street expectations, leaving room for short-term disappointment if execution stalls. GlobeNewsWire release
• Negative Sentiment: Shareholder scrutiny — A law firm announced an investigation into potential fiduciary breaches, which could create governance/legal overhang. PR Newswire

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.